NysnoBio

Gene therapies can correct diseases at their genetic core, but their success hinges on viral vector manufacturing. As gene therapy technology becomes more advanced, producing viral vectors becomes more challenging, requiring a manufacturing partner that is not only versed in viral vector production but also agile enough to adapt to the shifting tides of innovation. A closer look at the experiences of two companies -- NysnoBio, a client of UF Innovate | Accelerate, and bluebird bio -- offers insight into what sponsors at different stages of the development and manufacturing cycle need in a contract development and manufacturing organization (CDMO) partner.